

In re application of: Hastings et al.

Application Serial No.: 09/037,460

Art Unit: 1647

Filed: March 10, 1998

Examiner: Saoud, C.

For:

Human Vascular IBP-Like Growth Factor

Polynucleotides (as amended)

Attorney Docket No.: PF147D1

RESPONSE UNDER 37 C.F.R. § 1.116 TO PAPER NO. 24

Box AF

Washington, D.C. 20231

Sir:

In response to the Official Action mailed December 15, 2000 (Paper No. 24), Applicants hereby request that the following remarks be entered into the above-captioned application. Applicants submit concurrently herewith: (a) a Petition for Extension of Time for two (2) months up to and including May 15, 2001, accompanied by the appropriate fee; (b) a Fee Transmittal Sheet; and (c) a Notice of Appeal, accompanied by the appropriate fee.

Remarks

Claims 54-67, 75-92, 102-107, 115-119, and 122-175 are pending in the current application.

Rejections Under 35 U.S.C. § 101

The Examiner rejects claims 54-67, 75-92, 102-107, 115-119 and 122-175 under 35 U.S.C. § 101 alleging that the claimed invention is drawn to an invention with no apparent or disclosed specific and substantial credible utility.

More specifically, the Examiner alleges:

The instant application has provided a description of an isolated DNA encoding a protein and the protein encoded thereby. The instant application does not disclose the biological role of this protein or its significance.